Trials / No Longer Available
No Longer AvailableNCT04802083
COVID-19 Soliris Expanded Access Protocol
SOLIRIS® (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID-19) - An Expanded Access Protocol
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This protocol provides participants with COVID-19 access to Soliris.
Detailed description
This is an open-label, multicenter, expanded access protocol that will provide access to Soliris for participants diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection with a clinical presentation consistent with COVID-19 associated organ injury, such as acute respiratory distress syndrome, stroke, or acute renal failure. Participants who qualify for emergency treatment (whether in an inpatient or outpatient setting) will be offered the opportunity to receive up to 7 infusions of Soliris over approximately 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Eculizumab | Eculizumab 900-1200 mg will be administered intravenously. |
Timeline
- First posted
- 2021-03-17
- Last updated
- 2021-10-04
Source: ClinicalTrials.gov record NCT04802083. Inclusion in this directory is not an endorsement.